Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens.

Garrido C, Villacian J, Zahonero N, Pattery T, Garcia F, Gutierrez F, Caballero E, Van Houtte M, Soriano V, de Mendoza C; SINRES Group.

Antimicrob Agents Chemother. 2012 Jun;56(6):2873-8. doi: 10.1128/AAC.06170-11. Epub 2012 Mar 26.

2.

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD.

Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25.

3.

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, Si-Mohamed A, Piketty C.

HIV Med. 2008 Oct;9(9):765-70. doi: 10.1111/j.1468-1293.2008.00628.x. Epub 2008 Jul 21.

4.

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.

Malet I, Gimferrer Arriaga L, Artese A, Costa G, Parrotta L, Alcaro S, Delelis O, Tmeizeh A, Katlama C, Valantin MA, Ceccherini-Silberstein F, Calvez V, Marcelin AG.

J Antimicrob Chemother. 2014 Aug;69(8):2118-22. doi: 10.1093/jac/dku095. Epub 2014 Apr 7.

PMID:
24710029
5.

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.

AIDS. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60.

PMID:
19165083
6.

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Maïga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, Murphy R, Cissé M, Katlama C, Calvez V, Marcelin AG.

Antivir Ther. 2009;14(1):123-9.

PMID:
19320246
7.

Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.

Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF.

Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17.

8.

Emerging patterns and implications of HIV-1 integrase inhibitor resistance.

Geretti AM, Armenia D, Ceccherini-Silberstein F.

Curr Opin Infect Dis. 2012 Dec;25(6):677-86. doi: 10.1097/QCO.0b013e32835a1de7. Review.

PMID:
23086187
9.

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

Garrido C, de Mendoza C, Alvarez E, García F, Morello J, Garcia S, Ribera E, Rodríguez-Novoa S, Gutierrez F, Soriano V; Sinres Team.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):156-64. doi: 10.1089/AID.2010.0370. Epub 2011 May 6.

PMID:
21457126
10.

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.

da Silva D, Van Wesenbeeck L, Breilh D, Reigadas S, Anies G, Van Baelen K, Morlat P, Neau D, Dupon M, Wittkop L, Fleury H, Masquelier B.

J Antimicrob Chemother. 2010 Jun;65(6):1262-9. doi: 10.1093/jac/dkq099. Epub 2010 Apr 12.

PMID:
20388636
11.

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.

Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, Tchertanov L, Mouscadet JF.

Antimicrob Agents Chemother. 2010 Jan;54(1):491-501. doi: 10.1128/AAC.01075-09. Epub 2009 Nov 9.

12.

Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates.

Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ.

Antimicrob Agents Chemother. 2011 Jan;55(1):321-5. doi: 10.1128/AAC.01733-09. Epub 2010 Oct 18.

13.

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.

Canducci F, Ceresola ER, Saita D, Castagna A, Gianotti N, Underwood M, Burioni R, Lazzarin A, Clementi M.

J Antimicrob Chemother. 2013 Nov;68(11):2525-32. doi: 10.1093/jac/dkt220. Epub 2013 Jun 24.

PMID:
23798668
14.

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility.

Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ.

AIDS. 2008 Sep 12;22(14):1877-80. doi: 10.1097/QAD.0b013e32830f9703.

PMID:
18753927
15.

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

Gutiérrez C, Hernández-Novoa B, Pérez-Elías MJ, Moreno AM, Holguín A, Dronda F, Casado JL, Moreno S.

HIV Clin Trials. 2013 Jan-Feb;14(1):10-6. doi: 10.1410/hct1401-10.

PMID:
23372110
16.

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

Goethals O, Van Ginderen M, Vos A, Cummings MD, Van Der Borght K, Van Wesenbeeck L, Feyaerts M, Verheyen A, Smits V, Van Loock M, Hertogs K, Schols D, Clayton RF.

Antiviral Res. 2011 Aug;91(2):167-76. doi: 10.1016/j.antiviral.2011.05.011. Epub 2011 Jun 12.

PMID:
21669228
17.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram ME, Ram RR, Margot NA, Barnes TL, White KL, Callebaut C, Miller MD.

PLoS One. 2017 Feb 17;12(2):e0172206. doi: 10.1371/journal.pone.0172206. eCollection 2017.

18.

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.

Nguyen HL, Charpentier C, Nguyen N, de Truchis P, Molina JM, Ruxrungtham K, Delaugerre C.

HIV Med. 2013 Feb;14(2):85-91. doi: 10.1111/j.1468-1293.2012.01039.x. Epub 2012 Sep 20.

19.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4.

20.

Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials.

You J, Wang H, Huang X, Qin Z, Deng Z, Luo J, Wang B, Li M.

PLoS One. 2016 Aug 17;11(8):e0160087. doi: 10.1371/journal.pone.0160087. eCollection 2016.

Supplemental Content

Support Center